Clinical trial · no report yet · Phase 1
ONTRK
Study of ONO-7579 in Patients With Advanced Solid Tumors/ NTRK Gene Fusion Positive Advanced Solid Tumors
- NCT03182257 ↗
- Terminated
- Ono Pharmaceutical Co., Ltd.
- 3 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| YouTube | 2 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- An Open-label, Multi-center, Dose-escalation and Expansion Study to Evaluate the Safety and Efficacy of ONO-7579 in Patients With Advanced Solid Tumors/ NTRK Gene Fusion Positive Advanced Solid Tumors
- Phase
- Phase 1
- Status
- Terminated
- Conditions
- Solid Tumor
- Interventions
- ONO-7579
- Arms
- ONO-7579 Part A · Experimental
- ONO-7579 Part B · Experimental
- Enrollment
- 1
- Primary outcomes
- Part A: Incidence, nature and severity of Adverse Events
- Part A: Clinically significant changes in physical examinations
- Part A: Clinically significant changes in neurological examinations
- Part A: Clinically significant changes in vital signs and electrocardiogram - including the evaluation of the QT interval
- Part B: Overall Response Rate (ORR)
- Sponsor
- Ono Pharmaceutical Co., Ltd.
- Start
- Jul 12, 2017
- Primary completion
- Jan 30, 2018
- Results posted
- No
- Registry record
- NCT03182257 · updated Sep 13, 2019